Strategic Initiatives, Executive Transitions, and Strengthened Portfolios to
Increase Shareholder Value - Research Report on Trius, HCA, Alere, UHS, and
NEW YORK, August 5, 2013
NEW YORK, August 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Investors' Reports announced new research reports highlighting Trius
Therapeutics, Inc. (NASDAQ: TSRX), HCA Holdings, Inc. (NYSE: HCA), Alere Inc.
(NYSE: ALR), Universal Health Services Inc. (NYSE: UHS), and Bio-Reference
Laboratories Inc. (NASDAQ: BRLI). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.
Trius Therapeutics, Inc. Research Report
On July 30, 2013, Trius Therapeutics Inc. (Trius) and Cubist Pharmaceuticals
Inc. (Cubist) jointly announced a definitive agreement under which Cubist will
acquire all outstanding shares of Trius for $13.50 per share in cash or nearly
$707 million on a fully diluted basis. Jeffrey Stein, Ph.D., President and
Chief Executive Officer of Trius, said, "This transaction culminates years of
intense work by the Trius team to achieve this outcome, and our shareholders
are being rewarded for their involvement and support of the company."
According to the Companies, the agreement includes each Trius stockholder to
receive one Contingent Value Right (CVR), entitling the holder to receive an
additional cash payment of up to $2.00 for each share they own if certain
commercial sales milestones are achieved. The Full Research Report on Trius
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
HCA Holdings, Inc. Research Report
On July 29, 2013, HCA Holdings, Inc. (HCA) announced the retirement of Richard
M. Bracken as Chairman and Chief Executive Officer of the Company, who will
now transition as the Chairman of the Board at the end of 2013. R. Milton
Johnson will assume the position of HCA's Chief Executive Officer, effective
that same time. Bracken joined HCA in 1981 and has held several executive
leadership roles within the Company while Johnson has served the Company for
31 years. Johnson was named a member of the Company's Board of Directors in
2009 and assumed his current role as President in 2011. The Full Research
Report on HCA Holdings, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
Alere Inc. Research Report
On July 31, 2013, Alere Inc. (Alere) announced its Q2 2013 financial results
posting net revenue of $764 million compared to $700.5 million in Q2 2012. Net
loss attributable to common stockholders of the Company was $65.9 million or
$0.81 per diluted share, compared to $18.2 million or $0.23 in Q2 2012.
Non-GAAP adjusted net income per diluted share was $0.64 compared to $0.48 in
Q2 2012. Ron Zwanziger, Chairman, Chief Executive Officer and President of
Alere, said, "We are pleased to report a very strong quarter for Alere and
continued progress against the three-point strategic plan that we implemented
in November 2012. In particular, our currency adjusted organic growth rate for
our professional diagnostics segment, excluding changes in our U.S. Triage and
influenza revenues, was 8.6%, reflecting the strength of our
highly-differentiated portfolio across the globe. In addition, our combined
adjusted research and development and selling, general and administrative
expenses decreased as a percentage of revenue by 230 basis points from the
prior year quarter. Our growth rate in the quarter, coupled with disciplined
expense control, demonstrates our continued momentum and commitment to
enhancing value for our shareholders." The Full Research Report on Alere Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
Universal Health Services Inc. Research Report
On July 25, 2013, Universal Health Services, Inc. (UHS) announced its Q2 2013
financial results, reporting net income attributable to UHS of $151.8 million
or $1.53 per diluted share compared to $197.6 million or $1.10 per diluted
share in Q2 2012. Reported net revenues were up 6.5% YoY to $1.8 billion. The
Acute Care Services net revenues increased 4.9% YoY, whereas its Behavioral
Health Care Services net revenues increased 3.2% YoY. For H1 2013, the Company
reported net revenues of $3. 7 billion, compared to $3.5 billion in H1 2012.
The Full Research Report on Universal Health Services Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
Bio-Reference Laboratories Inc. Research Report
On July 22, 2013, Bio-Reference Laboratories Inc. (Bio-reference) announced
that it has signed a licensing agreement with the University of Washington to
make GeneTests.org, GeneClinics.org and all other related properties to become
a business unit of Bio-Reference. Vice President of Marketing for
Bio-Reference, Amar Kamath, commented, "We recognized that GeneTests.org has
been providing a community service since molecular genetics was in its
infancy, and we're pleased to be preserving and maintaining this valuable
resource free-of-charge to users." According to the Company, GeneTests.org has
been a main resource for physicians, geneticists and genetic counselors
seeking comprehensive information about testing for inherited disorders and
genetic counseling services since 1992. The Full Research Report on
Bio-Reference Laboratories Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by a CFA. However, we are only human and are prone to
make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
SOURCE Investors' Reports
Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
Press spacebar to pause and continue. Press esc to stop.